Composition of R&D Committee as of 15 June 2010
ORION CORPORATION STOCK EXCHANGE RELEASE 15 June 2010 AT 01.55 EET
The Board of Directors of Orion Corporation has decided to complement the composition of the R&D Committee with Matti Kavetvuo and Heikki Westerlund as new members as of 15 June 2010. Accordingly, all members of the Board of Directors belong to the R&D Committee.
Composition of the R&D Committee as of 15 June 2010:
Sirpa Jalkanen (Chairman)
Timo Lappalainen Olli Huotari
President and CEO SVP, Corporate Functions
Olli Huotari, SVP, Corporate Functions, phone +358 50 966 3054
Orionintie 1A, FI-02200 Espoo
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.
The Group's net sales in 2009 amounted to EUR 772 million. The Company invested EUR 95 million in research and development. At the end of 2009, the Group had a total of 3,100 employees, of whom 2,500 worked in Finland and 600 in other European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.